ZARONTIN

This brand name is authorized in Australia, Canada, Estonia, France, Ireland, Japan, New Zealand, United States

Active ingredients

The drug ZARONTIN contains one active pharmaceutical ingredient (API):

1 Aethosuximide
UNII 5SEH9X1D1D - ETHOSUXIMIDE

Ethosuximide is an anti-epileptic of the class of succinimides that apparently exerts multiple mechanisms of action. The activity of ethosuximide in absence type epilepsy seems to rely primarily on the inhibition of T-type calcium channels in the thalamus.

Read about Aethosuximide

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
N03AD01 Ethosuximide N Nervous system → N03 Antiepileptics → N03A Antiepileptics → N03AD Succinimide derivatives
Discover more medicines within N03AD01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: AU Pharmaceutical Benefits Scheme Identifier(s): 11703Y, 1413J, 1414K
Country: CA Health Products and Food Branch Identifier(s): 00022799, 00023485
Country: EE Ravimiamet Identifier(s): 1731057
Country: FR Base de données publique des médicaments Identifier(s): 68481191
Country: IE Health Products Regulatory Authority Identifier(s): 52850
Country: JP 医薬品医療機器総合機構 Identifier(s): 1139001Q1042
Country: NZ Medicines and Medical Devices Safety Authority Identifier(s): 1341, 1342
Country: US FDA, National Drug Code Identifier(s): 0071-0237, 0071-2418

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.